Artivion Past Earnings Performance
Past criteria checks 0/6
Artivion's earnings have been declining at an average annual rate of -20.4%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 8% per year.
Key information
-20.4%
Earnings growth rate
-19.1%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | 8.0% |
Return on equity | -0.3% |
Net Margin | -0.2% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Estimating The Fair Value Of Artivion, Inc. (NYSE:AORT)
Dec 19When Should You Buy Artivion, Inc. (NYSE:AORT)?
Nov 07Returns At Artivion (NYSE:AORT) Are On The Way Up
Sep 28Estimating The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)
Sep 06Is Artivion (NYSE:AORT) A Risky Investment?
Jun 28Data-Driven Growth Fuels More Upside For Overlooked Artivion
Jun 21Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher
May 08Is Artivion (NYSE:AORT) Using Too Much Debt?
Jan 13Artivion Stock: A First Assessment
Dec 27Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump
Nov 23Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025
Oct 13Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)
Jul 20Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher
May 10Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet
Mar 09Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M
Feb 16Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold
Dec 18Artivion (NYSE:AORT) Is Making Moderate Use Of Debt
Sep 29Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver
Sep 27Revenue & Expenses Breakdown
How Artivion makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 385 | -1 | 191 | 29 |
30 Jun 24 | 377 | -8 | 189 | 29 |
31 Mar 24 | 368 | -10 | 188 | 28 |
31 Dec 23 | 354 | -31 | 185 | 29 |
30 Sep 23 | 340 | -24 | 180 | 29 |
30 Jun 23 | 329 | -28 | 175 | 35 |
31 Mar 23 | 320 | -29 | 171 | 36 |
31 Dec 22 | 314 | -19 | 166 | 39 |
30 Sep 22 | 314 | -41 | 170 | 40 |
30 Jun 22 | 309 | -17 | 168 | 38 |
31 Mar 22 | 305 | -15 | 163 | 38 |
31 Dec 21 | 299 | -15 | 161 | 36 |
30 Sep 21 | 287 | 2 | 145 | 33 |
30 Jun 21 | 280 | -12 | 141 | 28 |
31 Mar 21 | 258 | -13 | 135 | 26 |
31 Dec 20 | 253 | -17 | 137 | 24 |
30 Sep 20 | 255 | -14 | 143 | 23 |
30 Jun 20 | 258 | -11 | 143 | 23 |
31 Mar 20 | 275 | -5 | 145 | 24 |
31 Dec 19 | 276 | 2 | 143 | 23 |
30 Sep 19 | 274 | 2 | 148 | 24 |
30 Jun 19 | 271 | 3 | 140 | 23 |
31 Mar 19 | 268 | 1 | 140 | 23 |
31 Dec 18 | 263 | -3 | 141 | 23 |
30 Sep 18 | 248 | -5 | 128 | 23 |
30 Jun 18 | 227 | -5 | 127 | 22 |
31 Mar 18 | 207 | -2 | 116 | 21 |
31 Dec 17 | 190 | 4 | 101 | 19 |
30 Sep 17 | 182 | 9 | 100 | 17 |
30 Jun 17 | 183 | 11 | 96 | 16 |
31 Mar 17 | 182 | 10 | 94 | 15 |
31 Dec 16 | 180 | 11 | 92 | 13 |
30 Sep 16 | 175 | 10 | 78 | 12 |
30 Jun 16 | 167 | 9 | 76 | 11 |
31 Mar 16 | 155 | 7 | 74 | 11 |
31 Dec 15 | 146 | 4 | 72 | 10 |
30 Sep 15 | 143 | 3 | 74 | 10 |
30 Jun 15 | 144 | 3 | 76 | 9 |
31 Mar 15 | 143 | 6 | 74 | 8 |
31 Dec 14 | 145 | 7 | 74 | 9 |
30 Sep 14 | 142 | 14 | 72 | 9 |
30 Jun 14 | 141 | 15 | 69 | 9 |
31 Mar 14 | 140 | 15 | 68 | 9 |
31 Dec 13 | 141 | 16 | 68 | 8 |
Quality Earnings: AORT is currently unprofitable.
Growing Profit Margin: AORT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AORT is unprofitable, and losses have increased over the past 5 years at a rate of 20.4% per year.
Accelerating Growth: Unable to compare AORT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AORT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: AORT has a negative Return on Equity (-0.28%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 00:01 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Artivion, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Raymond Myers | Benchmark Company |
Jason Mills | Canaccord Genuity |
Raymond Myers | Emerging Growth Equities, Ltd. |